Collaboration - March 28, 2015
Astra, Innate Sign Agreement
Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca and MedImmune, AstraZeneca’s wholly-owned subsidiary. The deal focuses on the development of anti-NKG2A antibody, IPH2201, also in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor created by MedImmune, to fight cancer. The compound IPH2201 currently is in Phase II development. Under the terms of […]
Uncategorized - March 26, 2015
AZ Creates Scientific Review Bd.
AstraZeneca PLC has created a scientific review board to assess requests from external researchers to access patient-level data. The board of independent clinicians and academics has been developed as a part of the company’s commitment to groups including the European Federation of Pharmaceutical Industries and Associations, Pharmaceutical Research and Manufacturers of America Responsible Data Sharing […]
Collaboration - March 20, 2015
AstraZeneca, Daiichi Sankyo Ink Co-Commercialization Deal
AstraZeneca Thursday signed a co-commercialization agreement with Parsippany, N.J.-based Daiichi Sankyo, Inc. worth $825 million. According to the agreement, Daiichi Sankyo will pay AstraZeneca $200 million upfront and follow-up payments up to $625 million to handle manufacturing and sales of Movantik (naloxegol), a once-daily pill for people with opioid-induced constipation (OIC). AstraZeneca will oversee manufacturing […]
Collaboration - March 13, 2015
AZ Invests in PhaseBio Trial
PhaseBio Pharmaceuticals, Inc. a biopolymer-based drug manufacturer, has raised $40 million in a Series C round of funding, which includes a major share from AstraZeneca. Existing investors New Enterprise Associates, Hatteras Venture Partners and Johnson & Johnson Innovation were also involved in the financing round, according to BioSpace. “AstraZeneca is committed to bringing innovative treatments […]
Acquisition - March 12, 2015
AstraZeneca Buys More Respiratory Business
AstraZeneca recently acquired the rights to Actavis’ branded respiratory business in the US and Canada, according to a company announcement. As part of the agreement, AstraZeneca is paying Actavis $600 million of initial consideration and agreed to pay low single-digit royalties above a certain revenue threshold. AstraZeneca also paid Actavis an additional $100 million for […]
Agreement - March 9, 2015
AZ Expands Software Use
AstraZeneca has expanded its use of Elixir Software’s R&D workflow-management software, with a three-year contract, in part to support communication while it is moving offices in the United Kingdom from Alderley Park to Cambridge. This agreement will allow AstraZeneca to apply Elixir’s cloud-based software to other scientific areas. Elixir singled out the facilitation of scientific […]
